Interim report 2026
Filed with HKEX · Stock code 6855 · · 101 pages · English
Summary by 6ix AI
Ascentage Pharma Group International has released its interim report for the first half of the year, detailing corporate and financial information for the period. The report includes updates on the company's product pipeline and clinical progress of key candidates. It also highlights recent appointments within the management team and changes to the stock short name.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Ascentage Pharma Group International on 6ix
Earlier from Ascentage Pharma Group International
- Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
- CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
- Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
- Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
- Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Later from Ascentage Pharma Group International
- Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme
- Voluntary announcement - acquisition of shares by the chairman and executive director
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - Ascentage Pharma's Lisaftoclax granted breakthrough therapy designation in China for treatment-naive CLL/SLL
- Voluntary announcement - Ascentage Pharma to present data from multiple trials, including an oral presentation of APG-5918, at ASH annual meeting 2026
Follow Ascentage Pharma Group International into a list and get an email when it puts out news.
Follow Ascentage Pharma Group International